Docetaxel versus mitoxantrone in men with hormone-refractory prostate cancer

被引:0
|
作者
机构
来源
Nature Clinical Practice Oncology | 2008年 / 5卷 / 6期
关键词
D O I
10.1038/ncponc1115
中图分类号
学科分类号
摘要
引用
收藏
页码:300 / 300
相关论文
共 50 条
  • [1] Docetaxel versus mitoxantrone in men with hormone-refractory prostate cancer
    [J]. Nature Clinical Practice Urology, 2008, 5 (6): : 293 - 293
  • [2] A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer
    R Collins
    R Trowman
    G Norman
    K Light
    A Birtle
    E Fenwick
    S Palmer
    R Riemsma
    [J]. British Journal of Cancer, 2006, 95 : 457 - 462
  • [3] A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer
    Collins, R.
    Trowman, R.
    Norman, G.
    Light, K.
    Birtle, A.
    Fenwick, E.
    Palmer, S.
    Riemsma, R.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (04) : 457 - 462
  • [4] Docetaxel (Taxotere) in hormone-refractory prostate cancer
    Petrylak, DP
    [J]. SEMINARS IN ONCOLOGY, 2000, 27 (02) : 24 - 29
  • [5] Docetaxel and exisulind in hormone-refractory prostate cancer
    Ryan, CW
    Stadler, WM
    Vogelzang, NJ
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (04) : 56 - 61
  • [6] Docetaxel in hormone-refractory metastatic prostate cancer
    Oh, WK
    [J]. DRUGS, 2005, 65 (16) : 2296 - 2297
  • [7] Docetaxel for hormone-refractory prostate cancer Reply
    Damber, Jan-Erik
    Aus, Gunnar
    [J]. LANCET, 2008, 372 (9648): : 1461 - 1462
  • [10] Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer
    Islam R. Younis
    Daniel J. George
    Terence J. McManus
    Herbert Hurwitz
    Patricia Creel
    Andrew J. Armstrong
    Jing Jie Yu
    Kristina Bacon
    Gerald Hobbs
    Cody J. Peer
    William P. Petros
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 73 : 991 - 997